Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -78.00 -0.96% 8,063.00 8,038.00 8,040.00 8,265.00 8,029.00 8,222.00 5,348,144 16:35:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 19,468.2 2,864.2 178.5 45.4 124,905

AstraZeneca's Orpathys Conditionally Approved by China for Lung Cancer Patients

23/06/2021 7:36am

Dow Jones News

Astrazeneca (LSE:AZN)
Historical Stock Chart

From Jun 2021 to Sep 2021

Click Here for more Astrazeneca Charts.

By Anthony O. Goriainoff


AstraZeneca PLC said Wednesday that China has conditionally approved Orpathys for patients with non-small cell lung cancer and mesenchymal-to-epithelial transition gene alterations.

The pharmaceutical company said that continued approval is contingent upon the successful completion of a confirmatory trial, and that it was based on positive results from a Phase 2 trial conducted in the country.

"Orpathys demonstrated robust anti-tumor activity based on an independent review of objective response rate in the trial's primary endpoint and its disease control rate," the company said.

AstraZeneca said the approval of Orpathys follows a priority review designation by China's Center for Drug Evaluation of the National Medical Products Administration, and represents the first global regulatory approval for the MET tyrosine kinase inhibitor.


Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com


(END) Dow Jones Newswires

June 23, 2021 02:36 ET (06:36 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210919 00:06:36